Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria

Katalin Nagy, Kinga Székely-Szüts, Kamel Izeradjene, Leslie Douglas, Mike Tillman, Helga Barti-Juhász, Massimo Dominici, Carlotta Spano, Gian Luca Cervo, Pierfranco Conte, Janet A. Houghton, R. Mihalik, L. Kópper, I. Peták

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this synergism have been proven to be cell type specific. We therefore focused our investigation on TRAIL-resistant colon carcinoma cells in this study. DNA fragmentation, mitochondrial membrane depolarization and increased caspase-3-like enzyme activity was exclusively induced only by combined treatment with proteasome inhibitors (epoxomicin, MG132, bortezomib/PS-341) and TRAIL. The expression level of anti-apoptotic proteins (XIAP, survivin, Bcl-2, Bcl-XL), regulated by NF-κB transcription factor, was not effected by any of these treatments. TRAIL alone induced only partial activation of caspase-3 (p20), while the combination of TRAIL and proteasome inhibition led to the full proteolytic activation of caspase-3 (p17). Only the combination treatment induced marked membrane depolarization and the release of cytochrome c, HtrA2/Omi and Smac/DIABLO. Apoptosis-inducing factor (AIF) was not released in any of these conditions. These results are consistent with a model where the full activation of caspase-3 by caspase-8 is dependent on the release of Smac/DIABLO in response to the combined treatment. This molecular mechanism, independent of the inhibition NF-kB activity, may provide rationale for the combination treatment of colon carcinomas with proteasome inhibitors and recombinant TRAIL or agonistic antibody of TRAIL receptors.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalPathology and Oncology Research
Volume12
Issue number3
Publication statusPublished - 2006

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Proteasome Inhibitors
Mitochondria
Colon
Caspase 3
Apoptosis
Carcinoma
Apoptosis Inducing Factor
TNF-Related Apoptosis-Inducing Ligand Receptors
Apoptosis Regulatory Proteins
Caspase 8
NF-kappa B
Mitochondrial Membranes
DNA Fragmentation
Proteasome Endopeptidase Complex
Cytochromes c
Cell Death
Transcription Factors
Tumor Necrosis Factor-alpha
Ligands

Keywords

  • Bortezomib/PS-341
  • Colon carcinoma
  • Epoxomicin
  • MG132
  • Smac/DIABLO
  • TRAIL

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. / Nagy, Katalin; Székely-Szüts, Kinga; Izeradjene, Kamel; Douglas, Leslie; Tillman, Mike; Barti-Juhász, Helga; Dominici, Massimo; Spano, Carlotta; Cervo, Gian Luca; Conte, Pierfranco; Houghton, Janet A.; Mihalik, R.; Kópper, L.; Peták, I.

In: Pathology and Oncology Research, Vol. 12, No. 3, 2006, p. 133-142.

Research output: Contribution to journalArticle

Nagy, K, Székely-Szüts, K, Izeradjene, K, Douglas, L, Tillman, M, Barti-Juhász, H, Dominici, M, Spano, C, Cervo, GL, Conte, P, Houghton, JA, Mihalik, R, Kópper, L & Peták, I 2006, 'Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria', Pathology and Oncology Research, vol. 12, no. 3, pp. 133-142.
Nagy, Katalin ; Székely-Szüts, Kinga ; Izeradjene, Kamel ; Douglas, Leslie ; Tillman, Mike ; Barti-Juhász, Helga ; Dominici, Massimo ; Spano, Carlotta ; Cervo, Gian Luca ; Conte, Pierfranco ; Houghton, Janet A. ; Mihalik, R. ; Kópper, L. ; Peták, I. / Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. In: Pathology and Oncology Research. 2006 ; Vol. 12, No. 3. pp. 133-142.
@article{6d61b3b628754cd0a68c58579dea24a3,
title = "Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria",
abstract = "The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this synergism have been proven to be cell type specific. We therefore focused our investigation on TRAIL-resistant colon carcinoma cells in this study. DNA fragmentation, mitochondrial membrane depolarization and increased caspase-3-like enzyme activity was exclusively induced only by combined treatment with proteasome inhibitors (epoxomicin, MG132, bortezomib/PS-341) and TRAIL. The expression level of anti-apoptotic proteins (XIAP, survivin, Bcl-2, Bcl-XL), regulated by NF-κB transcription factor, was not effected by any of these treatments. TRAIL alone induced only partial activation of caspase-3 (p20), while the combination of TRAIL and proteasome inhibition led to the full proteolytic activation of caspase-3 (p17). Only the combination treatment induced marked membrane depolarization and the release of cytochrome c, HtrA2/Omi and Smac/DIABLO. Apoptosis-inducing factor (AIF) was not released in any of these conditions. These results are consistent with a model where the full activation of caspase-3 by caspase-8 is dependent on the release of Smac/DIABLO in response to the combined treatment. This molecular mechanism, independent of the inhibition NF-kB activity, may provide rationale for the combination treatment of colon carcinomas with proteasome inhibitors and recombinant TRAIL or agonistic antibody of TRAIL receptors.",
keywords = "Bortezomib/PS-341, Colon carcinoma, Epoxomicin, MG132, Smac/DIABLO, TRAIL",
author = "Katalin Nagy and Kinga Sz{\'e}kely-Sz{\"u}ts and Kamel Izeradjene and Leslie Douglas and Mike Tillman and Helga Barti-Juh{\'a}sz and Massimo Dominici and Carlotta Spano and Cervo, {Gian Luca} and Pierfranco Conte and Houghton, {Janet A.} and R. Mihalik and L. K{\'o}pper and I. Pet{\'a}k",
year = "2006",
language = "English",
volume = "12",
pages = "133--142",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria

AU - Nagy, Katalin

AU - Székely-Szüts, Kinga

AU - Izeradjene, Kamel

AU - Douglas, Leslie

AU - Tillman, Mike

AU - Barti-Juhász, Helga

AU - Dominici, Massimo

AU - Spano, Carlotta

AU - Cervo, Gian Luca

AU - Conte, Pierfranco

AU - Houghton, Janet A.

AU - Mihalik, R.

AU - Kópper, L.

AU - Peták, I.

PY - 2006

Y1 - 2006

N2 - The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this synergism have been proven to be cell type specific. We therefore focused our investigation on TRAIL-resistant colon carcinoma cells in this study. DNA fragmentation, mitochondrial membrane depolarization and increased caspase-3-like enzyme activity was exclusively induced only by combined treatment with proteasome inhibitors (epoxomicin, MG132, bortezomib/PS-341) and TRAIL. The expression level of anti-apoptotic proteins (XIAP, survivin, Bcl-2, Bcl-XL), regulated by NF-κB transcription factor, was not effected by any of these treatments. TRAIL alone induced only partial activation of caspase-3 (p20), while the combination of TRAIL and proteasome inhibition led to the full proteolytic activation of caspase-3 (p17). Only the combination treatment induced marked membrane depolarization and the release of cytochrome c, HtrA2/Omi and Smac/DIABLO. Apoptosis-inducing factor (AIF) was not released in any of these conditions. These results are consistent with a model where the full activation of caspase-3 by caspase-8 is dependent on the release of Smac/DIABLO in response to the combined treatment. This molecular mechanism, independent of the inhibition NF-kB activity, may provide rationale for the combination treatment of colon carcinomas with proteasome inhibitors and recombinant TRAIL or agonistic antibody of TRAIL receptors.

AB - The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this synergism have been proven to be cell type specific. We therefore focused our investigation on TRAIL-resistant colon carcinoma cells in this study. DNA fragmentation, mitochondrial membrane depolarization and increased caspase-3-like enzyme activity was exclusively induced only by combined treatment with proteasome inhibitors (epoxomicin, MG132, bortezomib/PS-341) and TRAIL. The expression level of anti-apoptotic proteins (XIAP, survivin, Bcl-2, Bcl-XL), regulated by NF-κB transcription factor, was not effected by any of these treatments. TRAIL alone induced only partial activation of caspase-3 (p20), while the combination of TRAIL and proteasome inhibition led to the full proteolytic activation of caspase-3 (p17). Only the combination treatment induced marked membrane depolarization and the release of cytochrome c, HtrA2/Omi and Smac/DIABLO. Apoptosis-inducing factor (AIF) was not released in any of these conditions. These results are consistent with a model where the full activation of caspase-3 by caspase-8 is dependent on the release of Smac/DIABLO in response to the combined treatment. This molecular mechanism, independent of the inhibition NF-kB activity, may provide rationale for the combination treatment of colon carcinomas with proteasome inhibitors and recombinant TRAIL or agonistic antibody of TRAIL receptors.

KW - Bortezomib/PS-341

KW - Colon carcinoma

KW - Epoxomicin

KW - MG132

KW - Smac/DIABLO

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=33750865641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750865641&partnerID=8YFLogxK

M3 - Article

C2 - 16998592

AN - SCOPUS:33750865641

VL - 12

SP - 133

EP - 142

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -